#JPM23: When will the IPO window open? What terms are startups getting? Here's what to expect from capital markets this year
Executive Editor Drew Armstrong sat down with Bayer’s business development leader Marianne De Backer, PwC’s pharma deals chief Roel Van den Akker, and Sofinnova Investments General Partner Maha Katabi to talk about the IPO environment, trends in public and private fundraising, how negotiations between companies have changed and where capital markets are headed in 2023. This transcript has been edited for brevity and clarity.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.